Immune Landscape Changes in MASLD and the Effects of 11β‐HSD1 Inhibition Revealed by Single‐Cell Mass Cytometry
PROTEOMICS – Clinical Applications · 2025
DOI: 10.1002/prca.70022 ↗Kurz gefasst
Fachartikel in der Zeitschrift PROTEOMICS – Clinical Applications, 2025. Verfasst von Zayakhuu Gerelkhuu und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Chemistry, Research Institute for Convergence of Basic Science, Hanyang University, Seoul, Republic of Korea. Hauptthemen laut MEDLINE: 11-beta-Hydroxysteroid Dehydrogenase Type 1, Single-Cell Analysis. Die Arbeit nennt 55 Literaturangaben. Gefördert von: Basic Science Research Program of the National Research Foundation (NRF) Ministry of Science and ICT, Institute of Information & Communications Technology Planning & Evaluation (IITP) Korea Government (MSIT), Hanyang University.
Abstract (Originalsprache)
Background
Metabolic dysfunction‐associated steatotic liver disease (MASLD) affects nearly one‐fourth of the global population, yet effective diagnostics and treatments remain limited. Systemic immune dysregulation plays a key role in MASLD pathogenesis, highlighting the value of immune profiling.
Methods
In this study, we used high‐dimensional single‐cell mass cytometry (CyTOF) to analyze peripheral blood mononuclear cells (PBMCs) from healthy donors ( n = 6), MASLD patients ( n = 4), and MASLD patients treated with an 11β‐hydroxysteroid dehydrogenase type 1 (11β‐HSD1) inhibitor ( n = 2). PBMCs were stained with a 29‐marker panel to identify 15 immune cell types and assess cytokine expression.
Results
MASLD patients showed increased CD8⁺ T cells, early NK cells, and monocytes, along with reductions in T H 2, T H 1, late NK, and Treg cells. Cytokine profiling revealed elevated IL‐6 expression in plasmacytoid dendritic cells and late NK cells, indicating systemic inflammation. Automated clustering (PhenoGraph, UMAP) identified NK and phagocytic subsets associated with disease and treatment. Notably, 11β‐HSD1 inhibition led to downregulation of pro‐inflammatory cytokines (e.g., IFN‐γ, IL‐6) and partial restoration of immune subsets.
Conclusions
These results offer a high‐resolution view of immune alterations in MASLD and suggest that 11β‐HSD1 inhibition may represent a promising immunomodulatory therapeutic strategy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Chemistry, Research Institute for Convergence of Basic Science, Hanyang University, Seoul, Republic of Korea.
- Institute of Next Generation Material Design, Hanyang University, Seoul, Republic of Korea.
- Department of Chemistry, College of Natural Sciences, Hanyang University, Seoul, Republic of Korea.
- College of Pharmacy, Daegu Catholic University, Gyeongsan, Republic of Korea.
- Department of Pharmacology, College of Medicine, Hanyang University, Seoul, Republic of Korea.
- Department of Clinical Pharmacology and Therapeutics, Hanyang University Seoul Hospital, Seoul, Republic of Korea.
ORCID-Profile: Tae Hyun Yoon
Förderung
- Basic Science Research Program of the National Research Foundation (NRF) Ministry of Science and ICT
- Institute of Information & Communications Technology Planning & Evaluation (IITP) Korea Government (MSIT)
- Hanyang University
Zitieren
APA
Gerelkhuu, Z., Park, S., Kim, Y., Lee, S. W., Jun, D. W., & Yoon, T. H. (2025). Immune Landscape Changes in MASLD and the Effects of 11β‐HSD1 Inhibition Revealed by Single‐Cell Mass Cytometry. PROTEOMICS – Clinical Applications. https://doi.org/10.1002/prca.70022
Vancouver
Gerelkhuu Z, Park S, Kim Y, Lee SW, Jun DW, Yoon TH. Immune Landscape Changes in MASLD and the Effects of 11β‐HSD1 Inhibition Revealed by Single‐Cell Mass Cytometry. PROTEOMICS – Clinical Applications. 2025. doi:10.1002/prca.70022
BibTeX
@article{Gerelkhuu2025,
author = {Gerelkhuu, Zayakhuu and Park, Sehee and Kim, Yun and Lee, Sang Won and Jun, Dae Won and Yoon, Tae Hyun},
title = {Immune Landscape Changes in MASLD and the Effects of 11β‐HSD1 Inhibition Revealed by Single‐Cell Mass Cytometry},
journal = {PROTEOMICS – Clinical Applications},
year = {2025},
doi = {10.1002/prca.70022}
}
EUVIMED